PCSK9 and familial hyperaldosteronism: However, subgroup results from the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) program, showed that statin-treated FH patients had a similar magnitude of risk reduction for hard cardiovascular events with the PCSK9 inhibitor bococizumab as did patients without FH, with no evidence of statistical heterogeneity [115].